What to watch with APOE and Wechseljahre?

The combination of APOE genotype (especially ε4) and menopausal hormonal changes is an area of active research. APOE ε4 is the strongest known genetic risk factor for late-onset Alzheimer's disease. During menopause, estrogen levels drop dramatically, and estrogen has protective effects on the brain. Studies suggest that women with APOE ε4 may be more vulnerable to this estrogen decline, potentially increasing their risk for cognitive decline. However, the evidence is not strong enough for clinical recommendations. A direct-to-consumer APOE test is not approved for disease prediction under German law (GenDG). What to watch: lifestyle factors (diet, exercise, cognitive stimulation) are especially important for APOE ε4 carriers. Hormone replacement therapy (HRT) in menopause is not recommended based solely on APOE status; risk-benefit assessment must be individual. No self-medication. Beware of marketing that pitches APOE tests as 'menopause boosters' – the evidence is insufficient.